Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2 Recruiting
153 enrolled
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Phase 2 Recruiting
20 enrolled
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Phase 2 Recruiting
75 enrolled
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
41 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 Recruiting
218 enrolled
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Phase 2 Recruiting
200 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 Recruiting
70 enrolled
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2 Recruiting
18 enrolled
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Recruiting
160 enrolled
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Phase 2 Recruiting
32 enrolled
DIVINE
Phase 2 Recruiting
532 enrolled
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Phase 2 Recruiting
100 enrolled
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Phase 2 Recruiting
900 enrolled
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 Recruiting
53 enrolled
APRE
Phase 2 Recruiting
130 enrolled
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 Recruiting
152 enrolled
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Phase 2 Recruiting
80 enrolled
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Phase 2 Recruiting
20 enrolled
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Phase 2 Recruiting
27 enrolled
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
180 enrolled
Pola-ZR2P in Previously Untreated DLBCL
Phase 2 Recruiting
80 enrolled
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Phase 2 Recruiting
50 enrolled
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Phase 2 Recruiting
100 enrolled
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
582 enrolled
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Phase 2 Recruiting
90 enrolled
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Phase 2 Recruiting
60 enrolled
PARTOM
Phase 2 Recruiting
40 enrolled
FRONTJAK-001
Phase 2 Recruiting
88 enrolled
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Phase 2 Recruiting
37 enrolled
GUNS
Phase 2 Recruiting
315 enrolled
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
45 enrolled
REFRACT
Phase 2 Recruiting
284 enrolled
Go-CHOP as the Frontline Therapy for PTCL
Phase 2 Recruiting
45 enrolled